Pegozafermin and Leronlimab look to have very different mechanisms of action. They might produce a synergistic effect if trialed together. Ohm20 would be a better one to figure it out, than me. However, a quick peek shows that they might be good together. Additionally, Pegozafermin appears to have a decent safety profile. Unfortunately, 89Bio appears to have a similar cash position as Cytodyn, since their cash is dedicated to current trials. However, they have fewer outstanding shares (slightly less than 100 million). They have increased share count almost 500% in the last two years.